Treatment sequence
|
Subjects, n
|
Period
|
Subjects with abnormal response to ACTH stimulation, n
|
---|
1
|
2
|
3
|
Test 1
|
Test 2a
|
Test 3b
|
---|
| | |
(N = 37)
|
(N = 18)
|
(N = 2)
|
---|
A
|
5
|
Placebo
|
2.5 mg
|
10 mg
|
3
|
0
|
0
|
B
|
5
|
2.5 mg
|
5 mg
|
20 mg
|
5
|
0
|
0
|
C
|
5
|
5 mg
|
10 mg
|
40 mg
|
4
|
1
|
1c
|
D
|
5
|
10 mg
|
20 mg
|
60 mg
|
5
|
1
|
0
|
E
|
6d
|
20 mg
|
40 mg
|
Placebo
|
0
|
0
|
0
|
F
|
5
|
40 mg
|
60 mg
|
2.5 mg
|
0
|
0
|
0
|
G
|
6d
|
60 mg
|
Placebo
|
5 mg
|
1
|
0
|
0
|
Total
|
37
| |
18
|
2
|
1
|
- Doses shown correspond to the daily prednisone dose administered for 7 days in each treatment period
-
ACTH adrenocorticotropic hormone
-
aSubjects who failed Test 1 were re-tested 2 weeks later
-
bSubjects who failed Test 2 were re-tested 2 weeks later
-
cReturned to normal on Study Day 138
-
dOne subject in sequence E and one in sequence G discontinued the study during Period 2 and were replaced following approval by the study statistician, therefore n = 6 in these groups for this analysis